Publications by authors named "Brian Moser"

Claim this Profile
D
Diffusion Models, Image Super-Resolution, and Everything: A Survey.
Brian B Moser, Arundhati S Shanbhag, Federico Raue, Stanislav Frolov, Sebastian Palacio

IEEE Trans Neural Netw Learn Syst· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the ATLAS ITk pixel detector material via multiple scattering of positrons at the CERN PS.
Simon Florian Koch, Brian Moser, Antonín Lindner, Valerio Dao, Ignacio Asensi

Eur Phys J C Part Fields· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study.
Amita Datta-Mannan, Brian Moser, Wen Xu, Kimberley Jackson, Jennifer Witcher

Clin Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HHH whitepaper.
Hamza Abouabid, Abdesslam Arhrib, Hannah Arnold, Duarte Azevedo, Vuko Brigljevic, Brian Moser

Eur Phys J C Part Fields· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hitchhiker's Guide to Super-Resolution: Introduction and Recent Advances.
Brian B Moser, Federico Raue, Stanislav Frolov, Sebastian Palacio, Jorn Hees

IEEE Trans Pattern Anal Mach Intell· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Juan W Valle, Arndt Vogel, Crystal S Denlinger, Aiwu Ruth He, Li-Yuan Bai, Brian A Moser

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.
James M Martinez, Nada Hindiyeh, Greg Anglin, Kavita Kalidas, Michael E Hodsdon, Brian A Moser

Cephalalgia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Aiwu Ruth He, Roger B Cohen, Crystal S Denlinger, Ashwin Sama, Ariel Birnbaum, Brian Moser

Oncologist· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
James J Harding, Andrew X Zhu, Todd M Bauer, Toni K Choueiri, Alexander Drilon, Brian A Moser

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Brian A Moser, Elizabeth S LaBell, Emmanuel Chigutsa, Joseph A Jakubowski, David S Small

Clin Pharmacokinet· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Lee S Rosen, Jonathan W Goldman, Alain P Algazi, P Kellie Turner, Brian Moser

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TGF-1 Antibody Therapy in Patients with Diabetic Nephropathy.
James Voelker, Paul H Berg, Matthew Sheetz, Kevin Duffin, Tong Shen, Brian Moser

J Am Soc Nephrol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
Analia Azaro, Jordi Rodon, Antonio Calles, Irene Braña, Manuel Hidalgo, Brian A Moser

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Henrik Wagner, Dominick J Angiolillo, Jurrien M Ten Berg, Thomas O Bergmeijer, Joseph A Jakubowski, Brian A Moser

J Thromb Thrombolysis· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Lori Styles, Darell Heiselman, Lori E Heath, Brian A Moser, David S Small

J Pediatr Hematol Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Joseph A Jakubowski, Dominick J Angiolillo, Chunmei Zhou, David S Small, Brian A Moser

Thromb Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Dominick J Angiolillo, Joseph A Jakubowski, José Luis Ferreiro, Antonio Tello-Montoliu, Fabiana Rollini, Brian A Moser

J Am Coll Cardiol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
David Erlinge, Stefan James, Suman Duvvuru, Joseph A Jakubowski, Henrik Wagner, Brian A Moser

Thromb Haemost· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
David Erlinge, Paul A Gurbel, Stefan James, Tomas L Lindahl, Peter Svensson, Brian A Moser

J Am Coll Cardiol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
David Erlinge, Jurrien Ten Berg, David Foley, Dominick J Angiolillo, Henrik Wagner, Brian Moser

J Am Coll Cardiol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
Michael Man, Mark Farmen, Carmen Dumaual, Choo Hua Teng, Brian Moser

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis